Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Renal Cell 14Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Sarcoma, Ewing 3Ovarian Neoplasms 3Melanoma 3Kidney Neoplasms 3Pancreatic Neoplasms 2Osteosarcoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Medullary 2Breast Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Nivolumab 2cabozantinib 1Specimen Handling 1Platinum Compounds 1Methoxsalen 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Crohn Disease × cabozantinib × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡